Zkusit zdarma
BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

BBIO
Cena:
$ 69.12
-1.16 (-1.65%)
Valuace
100
Růst
50
Zdraví
50
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

1:04 13-05-2026

BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas t...

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

0:20 13-05-2026

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcri...

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

7:30 12-05-2026

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstr...

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

9:30 11-05-2026

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus ...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

16:01 08-05-2026

PALO ALTO, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeB...

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

11:31 08-05-2026

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript...

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

18:26 07-05-2026

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus...

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

16:01 07-05-2026

PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“Bridge...

BridgeBio to Participate in May and June Investor Conferences

BridgeBio to Participate in May and June Investor Conferences

16:01 06-05-2026

PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“Bridge...

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

7:30 06-05-2026

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM stu...

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE

7:30 05-05-2026

PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“Bridge...

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

7:30 04-05-2026

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“Bridge...

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

7:30 30-04-2026

PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“Brid...

BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore

BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore

17:58 29-04-2026

BridgeBio remains a compelling Buy, driven by Attruby's strong U.S. launch and favorable competitive...

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know

11:09 28-04-2026

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likel...

B. Metzler seel. Sohn & Co. AG Cuts Position in BridgeBio Pharma, Inc. $BBIO

B. Metzler seel. Sohn & Co. AG Cuts Position in BridgeBio Pharma, Inc. $BBIO

3:46 27-04-2026

B. Metzler seel. Sohn and Co. AG reduced its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 29.3%...

Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO

Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO

3:32 31-03-2026

Assenagon Asset Management S.A. trimmed its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 87....

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

15:30 30-03-2026

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in AC...

Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO

Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO

4:30 16-03-2026

Cinctive Capital Management LP trimmed its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 50.8% d...

BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress

BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress

7:47 12-03-2026

Limb-girdle muscular dystrophy type R9 (LGMDR9, formerly 2I) is a rare genetic disease caused by mut...

close

BRIDGEBIO REPORTS POSITIVE PHASE 3 TOPLINE RESULTS FOR ORAL INFIGRATINIB WITH THE FIRST STATISTICALLY SIGNIFICANT IMPROVEMENTS IN BODY PROPORTIONALITY IN ACHONDROPLASIA

12-02-2026
- PROPEL 3 SUCCESSFULLY MET THE PRIMARY ENDPOINT OF CHANGE FROM BASELINE IN AHV AT WEEK 52 (P...
Více zde

CORRECTING AND REPLACING -- BRIDGEBIO PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

27-01-2026
PALO ALTO, CALIF., JAN. 27, 2026 (GLOBE NEWSWIRE) -- IN A RELEASE ISSUED UNDER THE SAME HEADLINE EAR...
Více zde

BRIDGEBIO PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

27-01-2026
PALO ALTO, CALIF., JAN. 27, 2026 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO PRICES OFFERING OF $550 MILLION CONVERTIBLE SENIOR NOTES DUE 2033 TO PREFUND REPAYMENT OF CONVERTIBLE SENIOR NOTES DUE 2027

16-01-2026
PALO ALTO, CALIF., JAN. 15, 2026 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (THE “C...
Více zde

BRIDGEBIO CONTINUES LONG TERM DEBT MANAGEMENT STRATEGY AND ANNOUNCES PROPOSED OFFERING OF CONVERTIBLE SENIOR NOTES DUE 2033 TO PREFUND REPAYMENT OF CONVERTIBLE SENIOR NOTES DUE 2027

14-01-2026
-- THE TRANSACTION IS INTENDED TO STRENGTHEN THE BALANCE SHEET, LOWER INTEREST EXPENSE, REDUCE DILUT...
Více zde

BRIDGEBIO ANNOUNCES COMMERCIAL PROGRESS, PROGRAM UPDATES, AND 2026 MILESTONES AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

12-01-2026
-  PRELIMINARY UNAUDITED Q4 AND FULL YEAR 2025 NET ATTRUBY ® PRODUCT REVENUE OF $146.0 MILLION AND...
Více zde

BRIDGEBIO TO PARTICIPATE IN THE J.P. MORGAN HEALTHCARE CONFERENCE

05-01-2026
PALO ALTO, CALIF., JAN. 05, 2026 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO TO HOST ACHONDROPLASIA INVESTOR WEBINAR ON FRIDAY, JANUARY 9TH AT 8:00 AM ET

02-01-2026
PALO ALTO, CALIF., JAN. 02, 2026 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

22-12-2025
PALO ALTO, CALIF., DEC. 22, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO TO PARTICIPATE IN DECEMBER INVESTOR CONFERENCES

25-11-2025
PALO ALTO, CALIF., NOV. 25, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

19-11-2025
PALO ALTO, CALIF., NOV. 19, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

ACORAMIDIS SIGNIFICANTLY REDUCES ALL-CAUSE MORTALITY IN THE OVERALL ATTR-CM VARIANT AND V142I (V122I) POPULATIONS

08-11-2025
- SIMULTANEOUSLY PUBLISHED IN JAMA CARDIOLOGY ALONG WITH MODERATED POSTERS AT AHA, ACORAMIDIS DEMONS...
Více zde

NATIONAL ADVERTISING DIVISION WILL REFER BRIDGEBIO PHARMA TO GOVERNMENT AGENCIES FOR FAILURE TO PARTICIPATE IN INQUIRY

07-11-2025
FOLLOWING A CHALLENGE SUBMITTED BY PFIZER, INC., BBB NATIONAL PROGRAMS' NATIONAL ADVERTISING DIVISIO...
Více zde

BRIDGEBIO TO PARTICIPATE IN NOVEMBER INVESTOR CONFERENCES

04-11-2025
PALO ALTO, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO TO PRESENT DATA FROM THE OVERALL ATTR-CM VARIANT AND V142I (V122I) POPULATIONS FROM ATTRIBUTE-CM AT THE AHA SCIENTIFIC SESSIONS 2025

03-11-2025
PALO ALTO, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

29-10-2025
PALO ALTO, CALIF., OCT. 29, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO REPORTS POSITIVE PHASE 3 TOPLINE RESULTS FOR ENCALERET IN PATIENTS WITH AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1

29-10-2025
- THE CALIBRATE STUDY OF ENCALERET FOR PATIENTS WITH ADH1 MET ALL PRE-SPECIFIED PRIMARY AND KEY SECO...
Více zde

BRIDGEBIO TO REPORT PHASE 3 RESULTS FOR ENCALERET IN ADH1 CALIBRATE STUDY ON WEDNESDAY, OCTOBER 29TH

28-10-2025
PALO ALTO, CALIF., OCT. 28, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO REPORTS POSITIVE PHASE 3 RESULTS FOR SMALL MOLECULE BBP-418 IN LGMD2I/R9 FORTIFY STUDY

27-10-2025
- ALL PRIMARY AND SECONDARY INTERIM ANALYSIS ENDPOINTS IN FORTIFY PHASE 3 STUDY SUCCESSFULLY ACHIEVE...
Více zde

BRIDGEBIO TO REPORT PHASE 3 RESULTS FOR SMALL MOLECULE BBP-418 IN LGMD2I/R9 FORTIFY STUDY, ALONG WITH THIRD QUARTER 2025 FINANCIAL RESULTS NEXT WEEK

24-10-2025
PALO ALTO, CALIF., OCT. 24, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-10-2025
PALO ALTO, CALIF., OCT. 03, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

ACORAMIDIS BEGINS TO REDUCE CUMULATIVE CARDIOVASCULAR OUTCOMES WITHIN THE FIRST MONTH OF TREATMENT IN PATIENTS WITH ATTR-CM

28-09-2025
- BY MONTH 1, NUMERICALLY FEWER CUMULATIVE EVENTS WERE OBSERVED WITH ACORAMIDIS COMPARED TO PLACEBO ...
Více zde

BRIDGEBIO TO PRESENT ADDITIONAL CARDIOVASCULAR OUTCOMES DATA FROM ATTRIBUTE-CM AT THE HFSA ANNUAL SCIENTIFIC MEETING 2025

22-09-2025
PALO ALTO, CALIF., SEPT. 22, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRID...
Více zde

BRIDGEBIO PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

10-09-2025
PALO ALTO, CALIF., SEPT. 10, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRID...
Více zde

ENCALERET SHOWED PARATHYROID HORMONE-INDEPENDENT NORMALIZATION OF BLOOD AND URINE CALCIUM IN PHASE 2 PROOF-OF-CONCEPT STUDY IN POST-SURGICAL HYPOPARATHYROIDISM

06-09-2025
- 80% OF POST-SURGICAL HYPOPARATHYROIDISM PARTICIPANTS ACHIEVED CONCOMITANT BLOOD AND 24-HOUR URINE ...
Více zde

BRIDGEBIO TO HOST AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) INVESTOR WEBINAR ON WEDNESDAY, SEPTEMBER 10TH AT 8:00 AM ET

03-09-2025
PALO ALTO, CALIF., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRID...
Více zde

BRIDGEBIO TO PRESENT PHASE 2 PROOF-OF-CONCEPT DATA FOR ENCALERET IN POST-SURGICAL HYPOPARATHYROIDISM

02-09-2025
PALO ALTO, CALIF., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRID...
Více zde

ACORAMIDIS DEMONSTRATES STATISTICALLY SIGNIFICANT REDUCTION IN CARDIOVASCULAR MORTALITY (CVM) THROUGH MONTH 42 OF THE ATTRIBUTE-CM OPEN LABEL EXTENSION

30-08-2025
- ACORAMIDIS DEMONSTRATED A SIGNIFICANT REDUCTION IN RISK OF CVM THROUGH 42 MONTHS POST-RANDOMIZATIO...
Více zde

BRIDGEBIO TO PRESENT ADDITIONAL OPEN-LABEL EXTENSION DATA FROM ATTRIBUTE-CM AT ESC CONGRESS 2025

25-08-2025
PALO ALTO, CALIF., AUG. 25, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (“BRIDG...
Více zde

BRIDGEBIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

05-08-2025
- AS OF AUGUST 1, 2025, 3,751 UNIQUE PATIENT PRESCRIPTIONS HAVE BEEN WRITTEN BY 1,074 UNIQUE PRESCRI...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-12 00:00:008-KStáhnout
2026-01-21 00:00:008-KStáhnout
2026-01-12 00:00:008-KStáhnout
2025-10-29 00:00:008-KStáhnout
2025-10-29 00:00:0010-QStáhnout
2025-10-27 00:00:008-KStáhnout
2025-08-05 01:00:008-KStáhnout
2025-08-05 01:00:0010-QStáhnout
2025-08-05 00:00:008-KStáhnout
2025-08-05 00:00:0010-QStáhnout
2025-07-02 01:00:008-KStáhnout
2025-07-02 00:00:008-KStáhnout
2025-06-23 01:00:008-KStáhnout
2025-06-23 00:00:008-KStáhnout
2025-04-29 01:00:008-KStáhnout
2025-04-29 01:00:0010-QStáhnout
2025-04-29 00:00:008-KStáhnout
2025-04-29 00:00:0010-QStáhnout
2025-03-17 00:00:008-KStáhnout
2025-03-16 23:00:008-KStáhnout
2025-02-28 00:00:008-KStáhnout
2025-02-27 23:00:008-KStáhnout
2025-02-20 00:00:008-KStáhnout
2025-02-20 00:00:0010-KStáhnout
2025-02-19 23:00:008-KStáhnout
2025-02-19 23:00:0010-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-11-25 00:00:008-KStáhnout
2024-11-24 23:00:008-KStáhnout
2024-11-12 00:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-09-11 01:00:008-KStáhnout
2024-09-11 00:00:008-KStáhnout
2024-08-21 01:00:008-KStáhnout
2024-08-21 00:00:008-KStáhnout
2024-08-01 01:00:008-KStáhnout
2024-08-01 01:00:0010-QStáhnout
2024-08-01 00:00:008-KStáhnout
2024-08-01 00:00:0010-QStáhnout
2024-07-23 01:00:008-KStáhnout
2024-07-23 00:00:008-KStáhnout
2024-06-24 01:00:008-KStáhnout
2024-06-24 00:00:008-KStáhnout
2024-06-06 01:00:008-KStáhnout
2024-06-06 00:00:008-KStáhnout
2024-05-02 01:00:008-KStáhnout
2024-05-02 01:00:0010-QStáhnout
2024-05-02 00:00:008-KStáhnout
2024-05-02 00:00:0010-QStáhnout
2024-03-06 00:00:008-KStáhnout
2024-03-05 23:00:008-KStáhnout
2024-03-04 00:00:008-KStáhnout
2024-03-03 23:00:008-KStáhnout
2024-02-22 00:00:008-KStáhnout
2024-02-22 00:00:0010-KStáhnout
2024-02-21 23:00:008-KStáhnout
2024-02-21 23:00:0010-KStáhnout
2024-01-18 00:00:008-KStáhnout
2024-01-17 23:00:008-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2023-11-02 00:00:008-KStáhnout
2023-11-02 00:00:0010-QStáhnout
2023-11-01 23:00:008-KStáhnout
2023-11-01 23:00:0010-QStáhnout
2023-09-25 01:00:008-KStáhnout
2023-09-25 00:00:008-KStáhnout
2023-08-03 01:00:008-KStáhnout
2023-08-03 01:00:0010-QStáhnout
2023-08-03 00:00:008-KStáhnout
2023-08-03 00:00:0010-QStáhnout
2023-07-17 01:00:008-KStáhnout
2023-07-17 00:00:008-KStáhnout
2023-06-22 01:00:008-KStáhnout
2023-06-22 00:00:008-KStáhnout
2023-05-04 01:00:008-KStáhnout
2023-05-04 01:00:0010-QStáhnout
2023-05-04 00:00:008-KStáhnout
2023-05-04 00:00:0010-QStáhnout
2023-03-09 00:00:008-KStáhnout
2023-03-08 23:00:008-KStáhnout
2023-03-06 00:00:008-KStáhnout
2023-03-05 23:00:008-KStáhnout
2023-02-23 00:00:008-KStáhnout
2023-02-23 00:00:0010-KStáhnout
2023-02-22 23:00:008-KStáhnout
2022-12-06 00:00:008-KStáhnout
2022-12-05 23:00:008-KStáhnout
2022-11-03 00:00:008-KStáhnout
2022-11-03 00:00:0010-QStáhnout
2022-11-02 23:00:008-KStáhnout
2022-11-02 23:00:0010-QStáhnout
2022-09-23 01:00:008-KStáhnout
2022-09-23 00:00:008-KStáhnout
2022-08-04 01:00:008-KStáhnout
2022-08-04 01:00:0010-QStáhnout
2022-08-04 00:00:008-KStáhnout
2022-08-04 00:00:0010-QStáhnout
2022-07-26 01:00:008-KStáhnout
2022-07-26 00:00:008-KStáhnout
2022-06-24 01:00:008-KStáhnout
2022-06-24 00:00:008-KStáhnout
2022-05-18 01:00:008-KStáhnout
2022-05-18 00:00:008-KStáhnout
2022-05-13 01:00:008-KStáhnout
2022-05-13 00:00:008-KStáhnout
2022-05-10 01:00:008-KStáhnout
2022-05-10 00:00:008-KStáhnout
2022-05-05 01:00:0010-QStáhnout
2022-05-05 00:00:0010-QStáhnout
2022-02-25 00:00:0010-KStáhnout
2022-02-24 23:00:0010-KStáhnout
2022-02-24 00:00:008-KStáhnout
2022-02-23 23:00:008-KStáhnout
2021-12-27 00:00:008-KStáhnout
2021-12-26 23:00:008-KStáhnout
2021-12-16 00:00:008-KStáhnout
2021-12-15 23:00:008-KStáhnout
2021-11-18 00:00:008-KStáhnout
2021-11-17 23:00:008-KStáhnout
2021-11-04 00:00:008-KStáhnout
2021-11-04 00:00:0010-QStáhnout
2021-11-03 23:00:008-KStáhnout
2021-11-03 23:00:0010-QStáhnout
2021-10-26 01:00:008-KStáhnout
2021-10-26 00:00:008-KStáhnout
2021-08-23 01:00:008-KStáhnout
2021-08-23 00:00:008-KStáhnout
2021-08-13 01:00:008-KStáhnout
2021-08-13 00:00:008-KStáhnout
2021-08-05 01:00:0010-QStáhnout
2021-08-05 00:00:0010-QStáhnout
2021-06-22 01:00:008-KStáhnout
2021-06-22 00:00:008-KStáhnout
2021-06-01 01:00:008-KStáhnout
2021-06-01 00:00:008-KStáhnout
2021-05-14 01:00:008-KStáhnout
2021-05-14 00:00:008-KStáhnout
2021-05-11 01:00:008-KStáhnout
2021-05-11 00:00:008-KStáhnout
2021-05-06 01:00:0010-QStáhnout
2021-05-06 00:00:0010-QStáhnout
2021-04-15 01:00:008-KStáhnout
2021-04-15 00:00:008-KStáhnout
2021-03-31 01:00:008-KStáhnout
2021-03-31 00:00:008-KStáhnout
2021-02-26 00:00:008-KStáhnout
2021-02-25 23:00:008-KStáhnout
2021-02-25 00:00:0010-KStáhnout
2021-02-24 23:00:0010-KStáhnout
2021-02-17 00:00:008-KStáhnout
2021-02-16 23:00:008-KStáhnout
2021-01-29 00:00:008-KStáhnout
2021-01-28 23:00:008-KStáhnout
2021-01-26 00:00:008-KStáhnout
2021-01-25 23:00:008-KStáhnout
2021-01-20 00:00:008-KStáhnout
2021-01-19 23:00:008-KStáhnout
2021-01-12 00:00:008-KStáhnout
2021-01-11 23:00:008-KStáhnout
2021-01-04 00:00:008-KStáhnout
2021-01-03 23:00:008-KStáhnout
2020-11-06 00:00:008-KStáhnout
2020-11-05 23:00:008-KStáhnout
2020-11-05 00:00:008-KStáhnout
2020-11-05 00:00:0010-QStáhnout
2020-11-04 23:00:008-KStáhnout
2020-11-04 23:00:0010-QStáhnout
2020-10-23 01:00:008-KStáhnout
2020-10-23 00:00:008-KStáhnout
2020-10-06 01:00:008-KStáhnout
2020-10-06 00:00:008-KStáhnout
2020-10-05 01:00:008-KStáhnout
2020-10-05 00:00:008-KStáhnout
2020-09-29 01:00:008-KStáhnout
2020-09-29 00:00:008-KStáhnout
2020-08-11 01:00:008-KStáhnout
2020-08-11 01:00:0010-QStáhnout
2020-08-11 00:00:008-KStáhnout
2020-08-11 00:00:0010-QStáhnout
2020-06-24 01:00:008-KStáhnout
2020-06-24 00:00:008-KStáhnout
2020-06-08 01:00:008-KStáhnout
2020-06-08 00:00:008-KStáhnout
2020-05-14 01:00:0010-QStáhnout
2020-05-14 00:00:0010-QStáhnout
2020-05-13 01:00:008-KStáhnout
2020-05-13 00:00:008-KStáhnout
2020-04-29 01:00:008-KStáhnout
2020-04-29 00:00:008-KStáhnout
2020-03-24 00:00:008-KStáhnout
2020-03-23 23:00:008-KStáhnout
2020-03-10 00:00:008-KStáhnout
2020-03-09 23:00:008-KStáhnout
2020-03-06 00:00:008-KStáhnout
2020-03-05 23:00:008-KStáhnout
2020-03-04 00:00:008-KStáhnout
2020-03-03 23:00:008-KStáhnout
2020-03-03 00:00:0010-KStáhnout
2020-03-02 23:00:0010-KStáhnout
2020-03-02 00:00:008-KStáhnout
2020-03-01 23:00:008-KStáhnout
2020-02-19 00:00:008-KStáhnout
2020-02-18 23:00:008-KStáhnout
2020-01-07 00:00:008-KStáhnout
2020-01-06 23:00:008-KStáhnout
2019-12-26 00:00:008-KStáhnout
2019-12-25 23:00:008-KStáhnout
2019-12-17 00:00:008-KStáhnout
2019-12-16 23:00:008-KStáhnout
2019-11-19 00:00:008-KStáhnout
2019-11-18 23:00:008-KStáhnout
2019-11-08 00:00:0010-QStáhnout
2019-11-07 23:00:0010-QStáhnout
2019-10-11 01:00:008-KStáhnout
2019-10-11 00:00:008-KStáhnout
2019-09-12 01:00:008-KStáhnout
2019-09-12 00:00:008-KStáhnout
2019-08-14 01:00:0010-QStáhnout
2019-08-14 00:00:0010-QStáhnout
2019-07-03 01:00:008-KStáhnout
2019-07-03 00:00:008-KStáhnout
preloader